Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat PK and Safety in Patients with Renal Impairment
NCT02679131Phase 1Terminated
- Sponsor
- Acrotech Biopharma Inc
- Start
- Mar 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belinostat in solid tumor and hematologic malignancy (4 cohorts), sponsored by Acrotech Biopharma Inc. Primary endpoints: Area Under the Curve at 26 weeks, Volume of Distribution at Steady State at 26 weeks and 5 more. Started Mar 2016; status: terminated.
02
Drugs
belinostat
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT02679131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679131.